Report overview
An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
This report aims to provide a comprehensive presentation of the global market for Live Attenuated Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Vaccines. This report contains market size and forecasts of Live Attenuated Vaccines in global, including the following market information:
Global Live Attenuated Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Live Attenuated Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Live Attenuated Vaccines companies in 2022 (%)
The global Live Attenuated Vaccines market was valued at US$ 26690 million in 2022 and is projected to reach US$ 39700 million by 2029, at a CAGR of 5.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Examples of live attenuated) vaccines include: Viral: measles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; Bacterial: BCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.
We surveyed the Live Attenuated Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Live Attenuated Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Live Attenuated Vaccines Market Segment Percentages, by Type, 2022 (%)
Bacterial
Viral
Global Live Attenuated Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Live Attenuated Vaccines Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Research Institutes
Others
Global Live Attenuated Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Live Attenuated Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Live Attenuated Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Live Attenuated Vaccines revenues share in global market, 2022 (%)
Key companies Live Attenuated Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Live Attenuated Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Outline of Major Chapters:
Chapter 1: Introduces the definition of Live Attenuated Vaccines, market overview.
Chapter 2: Global Live Attenuated Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Live Attenuated Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Live Attenuated Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
